Harrow (HROW) Non Operating Investment Income (2018 - 2024)
Harrow (HROW) recorded quarterly Non Operating Investment Income of -$1.9 million in Q2 2024, down 54.09% quarter-over-quarter from -$1.2 million in Q1 2024, and down 169.33% on a YoY basis from $2.8 million in Q3 2023.
Harrow (HROW) Non Operating Investment Income (2018 - 2024) Analysis & Trends
Harrow's Non Operating Investment Income history runs 7 years deep, the most recent figure standing at -$1.9 million for Q2 2024.
- In Q2 2024, Non Operating Investment Income fell 169.33% year-over-year to -$1.9 million; the TTM figure through Dec 2024 stood at -$3.2 million (down 202.55% YoY), while the FY2024 annual figure was -$3.2 million, down 202.55% from the prior year.
- Non Operating Investment Income was -$1.9 million for Q2 2024 at Harrow, down from -$1.2 million in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $2.0 million in Q1 2023 to a low of -$3.6 million in Q2 2021.
- Historically, Non Operating Investment Income has averaged -$711666.7 across 5 years, with a median of -$735000.0 in 2020.
- The sharpest annual moves came in 2021 and 2023: Non Operating Investment Income plunged 736.28% in 2021, then surged 1369.06% in 2023.
- A 5-year view of Non Operating Investment Income shows it stood at $805000.0 in 2020, then sank by 284.72% to -$1.5 million in 2021, then jumped by 195.97% to $1.4 million in 2022, then tumbled by 70.85% to $416000.0 in 2023, then sank by 562.26% to -$1.9 million in 2024.
- The last three Non Operating Investment Income figures came in at -$1.9 million (Q2 2024), -$1.2 million (Q1 2024), and $416000.0 (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | - |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | - |
| 10 | Harrow | 1.34 Bn | 1.24 Bn | 27.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -1.92 Mn |
| Jun 30, 2024 | -1.92 Mn |
| Mar 31, 2024 | -1.25 Mn |
| Mar 31, 2024 | -1.25 Mn |
| Dec 31, 2023 | 416,000.00 |
| Dec 31, 2023 | 416,000.00 |
| Sep 30, 2023 | 1.35 Mn |
| Sep 30, 2023 | 1.35 Mn |
| Jun 30, 2023 | -714,000.00 |
| Jun 30, 2023 | -714,000.00 |
| Mar 31, 2023 | 2.04 Mn |
| Mar 31, 2023 | 2.04 Mn |
| Dec 31, 2022 | 1.43 Mn |
| Dec 31, 2022 | 1.43 Mn |
| Sep 30, 2022 | -1.03 Mn |
| Sep 30, 2022 | -1.03 Mn |
| Jun 30, 2022 | -3.45 Mn |
| Jun 30, 2022 | -3.45 Mn |
| Mar 31, 2022 | 139,000.00 |
| Mar 31, 2022 | 139,000.00 |